In March 2025, the company declared new designs for the direct-to-consumer giving of its Wegovy weight loss drug. The company recognized a fresh pharmacy, identified as NovoCare, which would charge prospects $499 a month for entry to the drug, under half the price of the drug by way of other pharmaceutical distribution networks.[53]Research of Rybe